Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

NCT07351487 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: Neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab

Sponsor

First Affiliated Hospital of Zhejiang University